EAST RUTHERFORD, N.J., July 30, 2019 (GLOBE NEWSWIRE) — Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to 15,000 sq. ft. The site currently has 50 employees and the expansion will add additional laboratory space to enable the recruitment of up to 40 more scientists, with the potential for further growth in the future.
Fit out is expected to begin in late August 2019 with a target completion date of the end of the year.
Cambrex’s Edinburgh site is a world-leader in providing solid form development services for drug substance and drug product. These include solid state investigations such as salt, co-crystal and polymorph screening, in addition to crystallization process development and GMP analytical services.
The expanded laboratory space will allow the installation of additional instruments and reactors for larger scale crystallization studies and solid form screening capabilities. Plans are in place for the installation of new ultra-performance liquid chromatography (UPLC) and gas chromatography instruments, as well as additional process analytical technology (PAT) tools.
“This strategic expansion, the increase in headcount and the investment in new equipment will enable us to serve more customers in the solid state screening market,” commented Mark Benger, Edinburgh Site Director, Cambrex. He added, “We have increasingly been asked by clients for additional services such as larger scale crystallization and we will now be able to provide these as well as adding greater efficiency and capacity at the Edinburgh site.”
Edinburgh became part of Cambrex’s global network of development and manufacturing facilities after the acquisition of Avista Pharma Solutions earlier this year. The facility was formerly known as Solid Form Solutions, an industry leader in solid state services, prior to the acquisition.
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.
For more information, please visit www.cambrex.com
Director, Marketing and Communications
Tel: +44 7803 443 155
Source: Cambrex Corporation